We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Serum Omentin-1 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2012 by Kocaeli Derince Education and Research Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01701830
First Posted: October 5, 2012
Last Update Posted: October 5, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Kocaeli Derince Education and Research Hospital
  Purpose
The aim of the study is to evaluate whether a low level of serum omentin-1 is associated with carotid atherosclerosis and mediated by inflammation.

Condition
Non-diabetic Chronic Kidney Disease Atherosclerosis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: The Relationship Between Serum Omentin-1 and IL-6 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease

Resource links provided by NLM:


Further study details as provided by Kocaeli Derince Education and Research Hospital:

Estimated Enrollment: 85
Study Start Date: October 2012
Estimated Study Completion Date: May 2013
Groups/Cohorts
Case Group
Patients with chronic kidney disease of stage 3-4.
Control group
30 healthy subject

Detailed Description:
Atherosclerotic cardiovascular disease is markedly increased in chronic kidney disease. There are a lot of risk factor, along with conventional risk factors. Serum onemtin-1 is a adipokine and suggested as a new marker for vascular disease.It has some anti-atherogenic properties. Studies investigating serum omentin-1 level have usually conducted in patients with diabetes mellitus.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Department of Nephrology, Check-up clinic
Criteria

Inclusion Criteria:

  • between ages of 18 - 65 years old chronic kidney disease of stage 3-4

Exclusion Criteria:

  • Chronic kidney disease of stage 5
  • The history of ischemic cardiovascular disease (myocardial infarction, unstable angina, stroke, peripheral artery disease, or cardiovascular revascularization)
  • Severe heart failure
  • Stage 2 hypertension
  • Diabetes mellitus
  • Corticosteroid therapy
  • Severe hepatic disease
  • Smoking
  • Inflammatory disease
  • Acute infectious disease
  • Malignancy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01701830


Locations
Turkey
Department of Nephrology, Check-up Clinic,Kocaeli Derince Education and Traning Hospital Recruiting
Izmit, Kocaeli, Turkey, 41100
Contact: Rabia TERZI, MD    90262 317 80 00 ext 8110    drrabia1@yahoo.com   
Principal Investigator: Erkan SENGUL, MD         
Sub-Investigator: Gokhan DUYGULU, MD         
Sub-Investigator: Sevim DINDAR, MD         
Sub-Investigator: Fatih BUNUL, MD         
Sponsors and Collaborators
Kocaeli Derince Education and Research Hospital
Investigators
Principal Investigator: Erkan SENGUL, MD Kocaeli Derince Education and Training Hospital
  More Information

Responsible Party: Kocaeli Derince Education and Research Hospital
ClinicalTrials.gov Identifier: NCT01701830     History of Changes
Other Study ID Numbers: 2012/02
First Submitted: October 3, 2012
First Posted: October 5, 2012
Last Update Posted: October 5, 2012
Last Verified: October 2012

Keywords provided by Kocaeli Derince Education and Research Hospital:
omentin-1
carotid atherosclerosis
kidney disease

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Atherosclerosis
Carotid Artery Diseases
Urologic Diseases
Renal Insufficiency
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases


To Top